NASDAQ$RPTX
Repare Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Repare Therapeutics reported fourth-quarter financial results, featuring revenue from collaboration agreements of $18.2 million and a net loss of $31.7 million. The company highlighted progress in its pipeline, including the collaboration with Roche on camonsertib and the Fast Track designation for RP-6306.
- Advanced camonsertib in partnership with Roche, with initial data expected in H1 2023.
- Reported initial Phase 1 clinical data for RP-6306 as a monotherapy for advanced solid tumors in the first half of 2023, and combination therapy data in Q4 2023.
- FDA granted Fast Track designation to RP-6306 in combination with gemcitabine for platinum-resistant ovarian cancer.
- Initiated IND-enabling studies for a small molecule against an undisclosed target, with potential clinical entry in late 2023 or early 2024.
Headline financials
Revenue & EPS history
Repare Therapeutics · Revenue · Quarterly
$18.2M
Forward guidance
Repare Therapeutics anticipates a productive 2023, with early clinical readouts for camonsertib and RP-6306 expected in the first half of the year and plans to expand its pipeline.
Tailwinds
- Initial data from Phase 1/2 trials of camonsertib in combination with PARP inhibitors expected in H1 2023.
- Initial data from the Phase 1/2 TRESR trial evaluating camonsertib in combination with gemcitabine expected in summer or fall 2023.
- Initial Phase 1 clinical data for RP-6306 as a monotherapy expected in H1 2023.
- Initial Phase 1 clinical data for RP-6306 as a combination therapy expected in Q4 2023.
- Initiation of IND-enabling studies for a small molecule against an undisclosed target in H1 2023.
Headwinds
- Prioritization of other Polθ inhibiting compounds may delay clinical entry for a Polθ inhibitor to 2024.
- Macroeconomic conditions, including the COVID-19 pandemic and rising inflation, could impact the business.
- Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
- Clinical trial site activation or enrollment rates that are lower than expected.
- Changes in the regulatory environment and the uncertainties of the regulatory approval process.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+19.7%
Q2 2023
Best reaction
-13.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -2.4% | +27.5% | +26.3% | |
| Q2 2025 | +0.0% | +3.3% | +11.2% | |
| Q1 2025 | +3.8% | +0.0% | +9.1% | |
| Q4 2024 | -1.7% | +0.9% | -9.4% | |
| Q3 2024 | -0.6% | -4.4% | -13.5% | |
| Q2 2024 | -4.8% | -8.3% | -11.9% | |
| Q1 2024 | +11.5% | +7.7% | +17.4% | |
| Q4 2023 | +4.4% | -0.6% | -29.9% | |
| Q3 2023 | -6.6% | — | — | |
| Q2 2023 | +19.7% | — | — | |
| Q1 2023 | +1.5% | — | — | |
| Q4 2022 | +2.0% | — | — | |
| Q3 2022 | +7.7% | — | — | |
| Q2 2022 | +0.2% | — | — | |
| Q1 2022 | -9.2% | — | — | |
| Q4 2021 | +0.4% | — | — | |
| Q3 2021 | +2.2% | — | — | |
| Q2 2021 | -0.2% | — | — | |
| Q1 2021 | +0.5% | — | — | |
| Q4 2020 | -13.5% | — | — | |
| Q3 2020 | -2.3% | — | — | |
| Q2 2020 | +2.6% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro